Royalty Pharma Bets $425M on AstraZeneca’s Cliramitug for ATTR-CM
Event summary
- Royalty Pharma acquires 3–4% royalty interest in AstraZeneca’s cliramitug from Neurimmune for up to $425M, including $125M upfront.
- Cliramitug is a Phase 3 TTR-fibril-depleting antibody targeting ATTR-CM, with results expected in 2028.
- ATTR-CM market grew over 40% in 2025 to >$7B, with AstraZeneca targeting $3–5B peak sales for cliramitug.
The big picture
Royalty Pharma’s acquisition of cliramitug royalties underscores the growing interest in ATTR-CM therapies, a market driven by unmet needs and rapid diagnostic advancements. The deal reflects Royalty Pharma’s strategy of funding late-stage biopharmaceutical innovations while positioning itself for long-term revenue streams from high-potential therapies.
What we're watching
- Clinical Success
- Whether cliramitug’s Phase 3 results in 2028 will validate its differentiated approach and support AstraZeneca’s peak sales projections.
- Market Dynamics
- The pace at which the ATTR-CM market continues to expand, given increasing diagnosis rates and new therapeutic options.
- Portfolio Strategy
- How Royalty Pharma’s second investment in ATTR-CM will integrate into its broader portfolio and contribute to long-term growth.
Related topics